Entrada Therapeutics, Inc.

NasdaqGM:TRDA Stock Report

Market Cap: US$622.8m

Entrada Therapeutics Future Growth

Future criteria checks 0/6

Entrada Therapeutics's revenue and earnings are forecast to decline at 67% and 58.7% per annum respectively while EPS is expected to decline by 59.4% per annum.

Key information

-58.7%

Earnings growth rate

-59.4%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate-67.0%
Future return on equityn/a
Analyst coverage

Good

Last updated05 Dec 2024

Recent future growth updates

Recent updates

There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Oct 17
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Aug 23
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Entrada Therapeutics: A Complicated Tale

Jun 16

Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

Mar 19
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Nov 09
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 26
Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 14
Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

Mar 08
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Sep 11
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02

Aug 11

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

May 28
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Jan 31
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Earnings and Revenue Growth Forecasts

NasdaqGM:TRDA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202629-181N/AN/A4
12/31/202547-139N/A-926
12/31/202418738N/A646
9/30/202421555-17-14N/A
6/30/2024239104-18-14N/A
3/31/202416323-94-89N/A
12/31/2023129-7134140N/A
9/30/202387-22111117N/A
6/30/202343-82109114N/A
3/31/202325-80127131N/A
12/31/2022N/A-95-97-94N/A
9/30/2022N/A-88-91-87N/A
6/30/2022N/A-78-77-74N/A
3/31/2022N/A-64-68-64N/A
12/31/2021N/A-51-55-51N/A
9/30/2021N/A-41-42-37N/A
6/30/2021N/A-34-33-29N/A
3/31/2021N/A-29-30-27N/A
12/31/2020N/A-27-28-26N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRDA's earnings are forecast to decline over the next 3 years (-58.7% per year).

Earnings vs Market: TRDA's earnings are forecast to decline over the next 3 years (-58.7% per year).

High Growth Earnings: TRDA's earnings are forecast to decline over the next 3 years.

Revenue vs Market: TRDA's revenue is expected to decline over the next 3 years (-67% per year).

High Growth Revenue: TRDA's revenue is forecast to decline over the next 3 years (-67% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TRDA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:09
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Entrada Therapeutics, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chris ShibutaniGoldman Sachs
Raghuram SelvarajuH.C. Wainwright & Co.
Boobalan PachaiyappanH.C. Wainwright & Co.